Skip to main content
  • 1813 Accesses

Abstract

Clinical signs and features include:

Bimodal incidence pattern—childhood and then age 50–70s; four to ten new cases per million; more common in women

Associated with internal malignancy in about 25 % of cases, especially adenocarcinoma of ovary, lung, and gastrointestinal tract in Western countries and nasopharyngeal carcinomas in South East Asia, Southern China, and North Africa; the diagnosis of dermatomyositis may be made prior to, concurrently, or after the diagnosis of malignancy; age-appropriate malignancy surveillance is recommended

Muscle symptoms: symmetric proximal muscle and truncal weakness that develops relatively slowly over the course of weeks to months, occasionally associated with myalgias and muscle tenderness early in the disease course. It is atypical for muscle disease to precede skin manifestations.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Khan S, Christopher-Stine L. Polymyositis, dermatomyositis, and autoimmune necrotizing myopathy: clinical features. Rheum Dis Clin North Am. 2011;37:143–58.

    Article  PubMed  Google Scholar 

  2. Ramos-E-Silva M, Carvalho JC, Carneiro SC. Cutaneous paraneoplasia. Clin Dermatol. 2011;29:541–7.

    Article  PubMed  Google Scholar 

  3. Zahr ZA, Baer AN. Malignancy in myositis. Curr Rheumatol Rep. 2011;13:208–15.

    Article  PubMed  Google Scholar 

  4. Nagaraju K, Lundberg IE. Polymyositis and dermatomyositis: pathophysiology. Rheum Dis Clin North Am. 2011;37:159–71.

    Article  PubMed  Google Scholar 

  5. Marie I, Mouthon L. Therapy of polymyositis and dermatomyositis. Autoimmun Rev. 2011;11:6–13.

    Article  PubMed  CAS  Google Scholar 

  6. Rowin J, Amato AA, Deisher N, et al. Mycophenolate mofetil in dermatomyositis: is it safe? Neurology. 2006;66:1245–7.

    Article  PubMed  CAS  Google Scholar 

  7. Dawkins MA, Jorizzo JL, Walker FO, et al. Dermatomyositis. A dermatology-based case series. J Am Acad Dermatol. 1998;38:397–404.

    Article  PubMed  CAS  Google Scholar 

  8. Kim JE, Jeong MG, Lee HE, et al. Successful treatment of cutaneous lesions of dermatomyositis with topical pimecrolimus. Ann Dermatol. 2011;23:348–51.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Liam Zakko .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Zakko, L., Finch, J., Rothe, M.J., Grant-Kels, J.M. (2013). Dermatomyositis: Dermatological Features. In: Wu, G., Selsky, N., Grant-Kels, J. (eds) Atlas of Dermatological Manifestations of Gastrointestinal Disease. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-6191-3_14

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-6191-3_14

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-6190-6

  • Online ISBN: 978-1-4614-6191-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics